Yaohong Pharmaceuticals (688176.SH): has repurchased 1.4651% of the shares accumulated.
On October 8, Gronghui reported that as of September 30, 2024, YAHONG Pharmaceuticals (688176.SH) has cumulatively repurchased 8,351,322 shares, accounting for 1.4651% of the total share capital. The highest price for repurchase transactions is RMB 6.73 per share, the lowest price is RMB 4.99 per share, and the total funds paid amount to RMB 47.787 million (excluding stamp duty, transaction commissions and other transaction costs).
Jiangsu Yahong Meditech Finishes Phase 2 Trial for Muscle-Invasive Bladder Cancer Pre-Treatment Combo
Yahong Medical (688176.SH): The Phase II clinical trial of APL-1202 oral combination with Toripalimab as neoadjuvant treatment for muscle-invasive bladder cancer has been completed and has shown positive efficacy signals.
On September 25th, Alphamab Oncology announced that the Phase II clinical trial of APL-1202 oral combination with toripalimab monoclonal antibody for muscle-invasive bladder cancer (MIBC) neoadjuvant therapy has completed Phase II clinical stage and achieved positive therapeutic efficacy signals. The main objective of this Phase II clinical trial is to evaluate the safety and efficacy of the combination of APL-1202 and toripalimab monoclonal antibody compared to toripalimab monotherapy as neoadjuvant therapy in MIBC subjects. The study population consists of subjects diagnosed with MIBC for the first time and planning to undergo radical cystectomy, who are intolerant or refuse to receive
Need To Know: Analysts Are Much More Bullish On Jiangsu Yahong Meditech Co., Ltd. (SHSE:688176) Revenues
Yahong Meditech Says APL1702 Drug's Trial Shows Positive Results; Shares Down 3%
Yahong Pharmaceuticals (688176.SH): The results of the APL-1702 international multicenter phase III clinical trial were selected for the 2024 International Photodynamic and Photodiagnosis Conference.
Yahong Pharmaceuticals (688176.SH) announced that recently, the company's product APL-1702 is used to treat advanced cervical cancer...
Yahong Medicine (688176.SH) released its semi-annual performance, with a net loss of 0.184 billion yuan.
Yahong Pharmaceutical (688176.SH) disclosed its 2024 interim report. During the reporting period, the company achieved revenue of 8,049...
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Yahong Medicine (688176.SH): plans to launch a restricted stock incentive plan for 8.3201 million shares.
Gelonghui announced on August 28th that YAHong Pharmaceuticals (688176.SH) has released a restricted stock incentive plan for 2024. The plan plans to grant 8.3201 million restricted stocks to the incentive recipients, accounting for approximately 1.46% of the total shares of the company's capital, which was 570 million shares at the time of the announcement of the incentive plan draft. The grant is a one-time grant with no reserved portions.
Yuhong Pharmaceutical (688176.SH): The revenue in Q2 of 2024 increased by 130.98% month-on-month, and the core products are steadily progressing to market.
On August 28, YAHONG Medicine (688176.SH) released its 2024 interim report. In the first half of 2024, the company achieved revenue of 80.4934 million yuan, with 56.1739 million yuan achieved in the second quarter, a 130.98% increase compared to the previous quarter. In addition, the company is actively promoting the market launch of two core products. The new drug application for APL-1702 has been accepted, and the company is actively advancing the market approval process. Currently, the progress is smooth, and it is expected to become the world's first non-surgical treatment for high-grade squamous intraepithelial lesions of the cervix. APL-1706 has also successfully passed the national drug approval process.
YaHong Medical (688176.SH): has repurchased 1.3608% of the shares.
On August 1st, Gelonhui announced that as of July 31, 2024, the company had cumulatively repurchased 7,756,291 shares, accounting for 1.3608% of the total share capital, with a maximum repurchase price of RMB 6.73 per share, and a minimum price of RMB 5.02 per share. The total amount paid was RMB 44.79 million (excluding stamp duty, transaction commission and other trading expenses).
Yahong Medicine (688176.SH): has repurchased 1.0685% of the shares cumulatively.
On July 3rd, Gelonhui reported that Yahong Medicine (688176.SH) has cumulatively repurchased 6,090,403 shares through centralized bidding trading as of July 3, 2024, accounting for 1.0685% of the total equity of the company. Compared with the previous disclosure, the proportion has increased by 0.4419%. The highest price for repurchase transactions was RMB 6.73 per share, the lowest price was RMB 5.08 per share, and the total amount paid was RMB 36,196,800 (excluding stamp duty, transaction commissions, and other transaction costs).
Yahong Pharmacy (688176.SH): the actual controller and financial person in charge have completed the shareholding, costing 4 million yuan.
Yahong Pharmaceutical (688176.SH) announced that as of July 2, 2024, the company's controlling shareholder and actual controller...
Yahong Meditech to Trial Drug Against Amoebae Infection
Yahong Pharmaceutical (688176.SH): APL-1202 clinical trial application has been approved by the National Medical Products Administration.
On June 24th, Gelunhui reported that Jiangsu Yahong Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "company") has received the drug clinical trial approval notice issued by the National Medical Products Administration (NMPA) for APL-1202, which is used to treat Free-living Amoebae (FLA) infection. This study is an evaluation of the use of hydroxychloroquine tablets (APL-1202) to treat Free-living Amoebae.
Yahong Pharmaceutical (688176.SH): The marketing application for APL-1702 (Hexyl Hydrochloride Ointment Photodynamic Therapy System) was accepted
Gelonghui, May 12 | Yahong Pharmaceutical (688176.SH) announced that the company recently received the “Notice of Acceptance” approved and issued by the National Drug Administration (NMPA). The company's product APL-1702 (generic name: aminonovalerate ointment photodynamic therapy system) is intended to treat high-grade cervical squamous intraepithelial lesion (HSIL) patients aged 18 and above to eliminate cancer in situ (HSIL) Accepted. APL-17
Yahong Pharmaceutical (688176.SH): A total of 0.6266% of shares have been repurchased
Gelonghui, May 6, 丨 Yahong Pharmaceutical (688176.SH) announced that as of April 30, 2024, the company had repurchased a total of 3,571,534 shares, accounting for 0.6266% of the company's total share capital. The highest price of the repurchase transaction was RMB 6.73 yuan/share, the lowest price was RMB 5.33 yuan/share, and the total capital paid was RMB 22.9833 million (excluding transaction fees such as stamp duty and transaction fees).
Yahong Pharmaceutical (688176.SH)'s revenue in the first quarter increased 126% month-on-month
On April 29, Yahong Pharmaceutical (stock code: 688176.SH) released its report for the first quarter of 2024. The company achieved revenue of 243.195 million yuan in the first quarter, an increase of 126.08% over the previous quarter. This was mainly due to the company's sales of commercial products, pezopanib tablets (trade name: Dipite) and neratinib maleate tablets (trade name: OUBI) during the reporting period. Depat and Oubi went on sale in October and December 2023 respectively, and product sales increased in the first quarter of this year.
Yahong Pharmaceutical (688176.SH) announced 2023 annual results, all core products are under development, and net loss increased to 400 million yuan
Yahong Pharmaceutical (688176.SH) disclosed its 2023 annual report. The company achieved operating income of 13 during the reporting period...
No Data
No Data